HER2 has been proposed as a rational therapeutic target because of its association with advanced-stage prostate cancer; however, prior clinical trials with anti-HER2 therapies, including lapatinib, pertuzumab, and trastuzumab, have shown limited clinical benefit (48–52, 72, 73). The gene discussed is ERBB2; the disease is Familial prostate cancer.